首页> 外文期刊>Nature >Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene.
【24h】

Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene.

机译:使用截短的促性腺素转基因改善mdx小鼠的营养不良表型。

获取原文
获取原文并翻译 | 示例
           

摘要

Duchenne muscular dystrophy (DMD) is a severe, progressive muscle-wasting disease that causes cardiac or respiratory failure and results in death at about 20 years of age. Replacement of the missing protein, dystrophin, using myoblast transfer in humans or viral/liposomal delivery in the mouse DMD model is inefficient and short-lived. One alternative approach to treatment would be to upregulate the closely related protein, utrophin, which might be able to compensate for the dystrophin deficiency in all relevant muscles. As a first step to this approach, we have expressed a utrophin transgene at high levels in the dystrophin-deficient mdx mouse. Our results indicate that high expression of the utrophin transgene in skeletal and diaphragm muscle can markedly reduce the dystrophic pathology. These data suggest that systemic upregulation of utrophin in DMD patients may lead to the development of an effective treatment for this devastating disorder.
机译:杜兴氏肌营养不良症(DMD)是一种严重的进行性肌肉萎缩性疾病,可导致心脏或呼吸衰竭,并在20岁左右死亡。使用人类中的成肌细胞转移或小鼠DMD模型中的病毒/脂质体递送来替代缺失的蛋白,肌营养不良蛋白效率低下且寿命短。一种替代的治疗方法是上调紧密相关的蛋白质utrophin,它可能能够补偿所有相关肌肉中的肌营养不良蛋白缺乏症。作为该方法的第一步,我们已在抗肌萎缩蛋白缺乏的mdx小鼠中高水平表达了卵磷脂的转基因。我们的研究结果表明,在骨骼肌和diaphragm肌中高表达的促肾上腺皮质激素转基因可以显着减少营养不良性病理。这些数据表明,DMD患者中的促性腺激素的系统上调可能导致开发针对这种破坏性疾病的有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号